Prospective randomized trials investigating optimal target INR for patients with antiphospholipid antibodies and thromboembolism.
| Study . | Treatment Arm . | Patients . | Patient- Years of Follow-Up . | Recurrent Thromboembolism . | Major Hemorrhagic Complications . |
|---|---|---|---|---|---|
| * Three of these patients were treated with aspirin alone as ‘standard’ antithrombotic therapy. They did not sustain any of the recurrent thromboembolic events or major hemorrhagic complications. | |||||
| Crowther, et al., 2003 21 | Target INR 2.0 to 3.0 | 58 | 158 | 2 | 4 |
| Target INR 3.1 to 4.0 | 56 | 148 | 6 | 3 | |
| Finazzi, et al., 2005 22 | Target INR 2.0 to 3.0 | 55* | 165 | 3 | 3 |
| Target INR 3.0 to 4.5 | 54 | 162 | 6 | 2 | |
| Study . | Treatment Arm . | Patients . | Patient- Years of Follow-Up . | Recurrent Thromboembolism . | Major Hemorrhagic Complications . |
|---|---|---|---|---|---|
| * Three of these patients were treated with aspirin alone as ‘standard’ antithrombotic therapy. They did not sustain any of the recurrent thromboembolic events or major hemorrhagic complications. | |||||
| Crowther, et al., 2003 21 | Target INR 2.0 to 3.0 | 58 | 158 | 2 | 4 |
| Target INR 3.1 to 4.0 | 56 | 148 | 6 | 3 | |
| Finazzi, et al., 2005 22 | Target INR 2.0 to 3.0 | 55* | 165 | 3 | 3 |
| Target INR 3.0 to 4.5 | 54 | 162 | 6 | 2 | |